FDA Authorized Wandercraft Eve Exoskeleton for US Sales
The commercial authorization marks a milestone for mobility aid accessibility for adults with spinal cord injuries.
Updated on Sept. 27, 2026 in Robotics
Live Poll
Do you believe wearable robotic suits will meaningfully improve daily life for those with mobility issues?
The FDA has cleared the Eve personal exoskeleton from Wandercraft for commercial sale in the United States. The motorized device is designed to assist adults with spinal cord injuries with everyday tasks.
Why it matters
The authorization expands the landscape of accessible robotic mobility aids, potentially providing a new option for standing and indoor movement for patients. It reflects an evolving regulatory pathway for assistive exoskeletons in the United States.
The Eve exoskeleton uses 12 motors in the hips, knees, and ankles to achieve a top speed of 0.25 meters per second. The device operates for 4 hours on a full charge and accommodates users up to 100 kg and 1.94 m in height.
The players
Wandercraft
A French robotics firm specializing in self-balancing exoskeletons and mobility-assistance hardware.
FDA
The United States federal agency responsible for regulating medical devices and consumer safety.
The details
Technicians calibrate the exoskeleton to a user's height, leg length, and joint flexibility to ensure correct alignment. Once fitted, the user operates the device via a joystick to toggle between sitting, standing, walking, and turning functions. The system is strictly intended for indoor use on flat surfaces and requires a certified caregiver to be present at all times for safety.
Timeline
September 2026: Wandercraft announced US commercial sales.
The Tech Race
The FDA approval follows a broader industry trend of transitioning self-balancing exoskeletons from clinical research settings into personal homes. This milestone positions the Eve device against existing rehabilitation-focused robots by specifically targeting daily living tasks like meal preparation.
Eligible users with spinal cord injuries can now access the device through coverage programs including Medicare, veterans' health systems, and workers' compensation. The system requires a certified caregiver for operation and is restricted to flat, indoor surfaces.
The takeaway
The FDA approval signals a shift toward bringing autonomous assistive robotics into the domestic environment for users with spinal cord injuries. Observers should track the expansion of insurance coverage parameters as more users begin clinical implementation.
Further reading
For more on the latest advancements in mobility hardware, visit our Robotics section.
Source note: This article includes information reported by New Atlas.
Live Poll
Do you believe wearable robotic suits will meaningfully improve daily life for those with mobility issues?
